Search

Your search keyword '"Braso-Maristany, F."' showing total 48 results
Start Over Author "Braso-Maristany, F."
48 results on '"Braso-Maristany, F."'

1. Unraveling the clinicopathological and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-low and HER2-0 breast cancer

Author

Schettini, F., Nucera, S., Brasó-Maristany, F., De Santo, I., Pascual, T., Bergamino, M., Galván, P., Conte, B., Seguí, E., García Fructuoso, I., Gómez Bravo, R., Rivera, P., Rodríguez, A.B., Martínez-Sáez, O., Ganau, S., Sanfeliu, E., González-Farre, B., Vidal Losada, M.J., Adamo, B., Cebrecos, I., Mension, E., Oses, G., Jares, P., Vidal-Sicart, S., Mollà, M., Muñoz, M., and Prat, A.

Published
2024
Full Text
View/download PDF

2. Prognostic value of HER2DX in early-stage HER2-positive breast cancer: a comprehensive analysis of 757 patients in the Sweden Cancerome Analysis Network—Breast dataset (SCAN-B)

Author

Villacampa, G., Pascual, T., Brasó-Maristany, F., Paré, L., Martínez-Sáez, O., Cortés, J., Ciruelos, E., Martin, M., Conte, P., Carey, L.A., Fernandez, A., Harbeck, N., Marín-Aguilera, M., Vivancos, A., Curigliano, G., Villagrasa, P., Parker, J.S., Perou, C.M., Prat, A., and Tolaney, S.M.

Published
2024
Full Text
View/download PDF

3. Analytical validation of HER2DX genomic test for early-stage HER2-positive breast cancer

Author

Marín-Aguilera, M., Jares, P., Sanfeliu, E., Villacampa, G., Hernández-lllán, E., Martínez-Puchol, A.I., Shankar, S., González-Farré, B., Waks, A.G., Brasó-Maristany, F., Pardo, F., Manning, D.K., Abery, J.A., Curaba, J., Moon, L., Gordon, O., Galván, P., Wachirakantapong, P., Castillo, O., Nee, C.M., Blasco, P., Senevirathne, T.H., Sirenko, V., Martínez-Sáez, O., Aguirre, A., Krop, I.E., Li, Z., Spellman, P., Metzger Filho, O., Polyak, K., Michaels, P., Puig-Butillé, J.A., Vivancos, A., Matito, J., Buckingham, W., Perou, C.M., Villagrasa-González, P., Prat, A., Parker, J.S., and Paré, L.

Published
2024
Full Text
View/download PDF

4. TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy

Author

Martín, M., Stecklein, S.R., Gluz, O., Villacampa, G., Monte-Millán, M., Nitz, U., Cobo, S., Christgen, M., Brasó-Maristany, F., Álvarez, E.L., Echavarría, I., Conte, B., Kuemmel, S., Bueno-Muiño, C., Jerez, Y., Kates, R., Cebollero, M., Kolberg-Liedtke, C., Bueno, O., García-Saenz, J.Á., Moreno, F., Grischke, E.-M., Forstbauer, H., Braun, M., Warm, M., Hackmann, J., Uleer, C., Aktas, B., Schumacher, C., Wuerstleins, R., Graeser, M., zu Eulenburg, C., Kreipe, H.H., Gómez, H., Massarrah, T., Herrero, B., Paré, L., Bohn, U., López-Tarruella, S., Vivancos, A., Sanfeliu, E., Parker, J.S., Perou, C.M., Villagrasa, P., Prat, A., Sharma, P., and Harbeck, N.

Published
2024
Full Text
View/download PDF

6. Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer

Author

Villacampa, G., Tung, N.M., Pernas, S., Paré, L., Bueno-Muiño, C., Echavarría, I., López-Tarruella, S., Roche-Molina, M., del Monte-Millán, M., Marín-Aguilera, M., Brasó-Maristany, F., Waks, A.G., Pascual, T., Martínez-Sáez, O., Vivancos, A., Conte, P.F., Guarneri, V., Vittoria Dieci, M., Griguolo, G., Cortés, J., Llombart-Cussac, A., Muñoz, M., Vidal, M., Adamo, B., Wolff, A.C., DeMichele, A., Villagrasa, P., Parker, J.S., Perou, C.M., Fernandez-Martinez, A., Carey, L.A., Mittendorf, E.A., Martín, M., Prat, A., and Tolaney, S.M.

Published
2023
Full Text
View/download PDF

8. 124O Patritumab deruxtecan (HER3-DXd) in hormonal receptor-positive/HER2-negative (HR+/HER2-) and triple-negative breast cancer (TNBC): Results of part B of SOLTI TOT-HER3 window of opportunity trial

Author

Oliveira, M., Pascual, T., Ortega, P. Tolosa, Vila, M. Margeli, Cejalvo, J.M., Jurado, J. Cruz, Bofill, F.J. Salvador, Arumi de Dios, M.A., Losada, M.J. Vidal, Simon, S. Pernas, Esker, S., Fan, P-D., Santhanagopal, A., Martínez-Sáez, O., Brasó-Maristany, F., Villacampa, G., Bayona, R. Sanchez, Ferrero-Cafiero, J.M., Falato, C., and Prat, A.

Published
2023
Full Text
View/download PDF

9. 126MO HER2DX and pathological complete response in HER2-positive breast cancer: A combined analysis of 4 neoadjuvant studies

Author

Waks, A.G., Villacampa, G., Brunet, L. Pare, Tung, N.M., Muiño, C. Bueno, Diaz-Guardamino, I. Echavarria, Lopez-Tarruella Cobo, S., Marín-Aguilera, M., Brasó-Maristany, F., Pascual, T., Saez, O. Martinez, Wolff, A.C., Demichele, A., Perou, C.M., Fernandez-Martinez, A., Carey, L.A., Mittendorf, E.A., Jimenez, M. Martin, Prat, A., and Tolaney, S.M.

Published
2023
Full Text
View/download PDF

10. 102P HER2DX risk-score in early-stage HER2-positive (HER2+) breast cancer: A correlative analysis of 757 patients from the Sweden Cancerome Analysis Network - Breast (SCAN-B) dataset

Author

Pascual, T., Villacampa, G., Brasó-Maristany, F., Brunet, L. Pare, Saez, O. Martinez, Cortés, J., Ciruelos, E.M., Jimenez, M. Martin, Conte, P.F., Carey, L.A., Fernandez-Martinez, A., Harbeck, N., Marín-Aguilera, M., Vivancos, A., Curigliano, G., Gonzalez, P. Villagrasa, Parker, J., Tolaney, S.M., Perou, C.M., and Prat, A.

Published
2023
Full Text
View/download PDF

13. 13P Analytical validation of HER2DX test for early-hER2+ breast cancer

Author

Torres, E. Sanfeliu, Marín-Aguilera, M., Jares, P., Villacampa, G., Hernández-Illán, E., Gonzalez-Farre, B., Brasó-Maristany, F., Galván, P., Castillo, O., Blasco, P., Sirenko, V., Aguirre, Á., Puig-Butille, J.A., Vivancos, A., Matito, J., Perou, C.M., Gonzalez, P. Villagrasa, Prat, A., Parker, J., and Brunet, L. Pare

Published
2023
Full Text
View/download PDF

14. 11P Independent validation of the HER2DX assay in HER2-positive (HER2+) breast cancer (BC) treated with neoadjuvant paclitaxel, trastuzumab and pertuzumab (THP): A correlative analysis from the BiOnHER study

Author

Grimalt, B. Fullana, Brasó-Maristany, F., Gómez, N., Petit, A., Ortega, R., Vicente, M., Falo, C., Stradella, A., Vazquez, S., Vazquez, R. Villanueva, Pla, M.J., Purqueras, E., Calaf, M., Brunet, L. Pare, Marín-Aguilera, M., Galván, P., Perou, C.M., Gonzalez, P. Villagrasa, Prat, A., and Simon, S. Pernas

Published
2023
Full Text
View/download PDF

15. 7P Independent validation of HER2DX ERBB2 mRNA score to predict HER2-positive (HER2+), HER2-low and HER2-0 status in breast cancer

Author

Torres, E. Sanfeliu, Villacampa, G., Pascual, T., Oliveira, M., Losada, M.J. Vidal, Bellet-Ezquerra, M., Gonzalez-Farre, B., Puig-Butille, J.A., Jares, P., Simon, S. Pernas, Muiño, C. Bueno, Jimenez, M. Martin, Tarantino, P., Waks, A.G., Mittendorf, E.A., Tolaney, S.M., Cortés, J., Cussac, A. Llombart, Prat, A., and Brasó-Maristany, F.

Published
2023
Full Text
View/download PDF

17. 8P First decision impact study of HER2DX in patients (pts) with HER2-positive (HER2+) early breast cancer

Author

Saez, O. Martinez, Brasó-Maristany, F., Marín-Aguilera, M., Losada, M.J. Vidal, Adamo, B., Pascual, T., Schettini, F., Conte, B., Chic, N., Bravo, R. Gomez, Fructuoso, I. Garcia, Solis, E. Segui, Galván, P., Hernández-Illán, E., Jares, P., Puig-Butille, J.A., Torres, E. Sanfeliu, Brunet, L. Pare, Gonzalez, P. Villagrasa, and Munoz, M.

Published
2023
Full Text
View/download PDF

20. 3MO HER2 expression and early response to patritumab deruxtecan (HER3-DXd) in early-stage hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer (BC): A correlative analysis from SOLTI-TOT-HER3 trial

Author

Brasó-Maristany, F., Oliveira, M., Ortega, P. Tolosa, Vila, M. Margeli, Jurado, J. Cruz, Bofill, F.J. Salvador, Cejalvo, J.M., Arumi de Dios, M.A., Losada, M.J. Vidal, Simon, S. Pernas, Esker, S., Fan, P-D., Santhanagopal, A., Saez, O. Martinez, Villacampa, G., Bayona, R. Sanchez, Ferrero-Cafiero, J.M., Falato, C., Pascual, T., and Prat, A.

Published
2023
Full Text
View/download PDF

22. 237MO TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy without immunotherapy

Author

Jimenez, M. Martin, Gluz, O., Villacampa, G., Lopez-Tarruella Cobo, S., Nitz, U.A., Cobo, S., Brasó-Maristany, F., Christgen, M., Gilarranz, Y. Jerez, Kummel, S., Conte, B., Diaz-Guardamino, I. Echavarria, Graeser-Mayer, M.K., Kreipe, H., Del Monte-Millan, M., Lopez, B. Herrero, Perou, C.M., Brunet, L. Pare, Prat, A., and Harbeck, N.

Published
2024
Full Text
View/download PDF

23. 147P Breast cancer in women with germline pathogenic variants: Frequency, clinical behavior, and outcomes of a consecutive series of patients from Spain

Author

Rodriguez Hernandez, A., primary, Braso Maristany, F., additional, Pastor, B., additional, Potrony, M., additional, Moreno, L., additional, Grau, E., additional, Puig-Butille, J.A., additional, Martinez Saez, O., additional, Conte, B., additional, Chic, N., additional, Vidal Losada, M.J., additional, Munoz, M., additional, Balaguer, F., additional, Prat, A., additional, and Adamo, B., additional

Published
2022
Full Text
View/download PDF

25. 275P Clinical and molecular impact of neoadjuvant chemotherapy (NACT) or endocrine therapy (NET) on hormone receptor positive (HR+)/HER2-negative (-) breast cancer (BC)

Author

Schettini, F., Brasó-Maristany, F., Pascual, T., Galván, P., Conte, B., Ghiglione, L., Falato, C., Martínez-Sáez, O., Chic, N., Rodriguez, A.B., Torres, E. Sanfeliu, Gonzalez-Farre, B., Losada, M.J. Vidal, Adamo, B., Cebrecos, I., Mension, E., Oses, G., Mollá, M., Munoz, M., and Prat, A.

Published
2023
Full Text
View/download PDF

26. 2246P Tumor-infiltrating lymphocites and gene expression across multiple cancer-types: A translational analysis from the SOLTI-1904-ACROPOLI study

Author

Solis, E. Segui, Torres, E. Sanfeliu, Gonzalez-Farre, B., Pascual, T., Brasó-Maristany, F., Galván, P., Farre, X. González, Salvador, F., Felip, E., Garralda, E., Paz-Ares, L., Juan, M., Nin, R. Mesia, Fernandez, A.M. Arance, Cervantes, A., Martin-Liberal, J., Javierre, G. Villacampa, Tabernero, J., and Prat, A.

Published
2023
Full Text
View/download PDF

27. 2239P Gene expression profiling in tumors with and without tertiary lymphoid structures across cancer-types

Author

Solis, E. Segui, Pascual, T., Torres, E. Sanfeliu, Gonzalez-farre, B., Brasó-Maristany, F., Farre, X. González, Salvador, F., Felip, E., Garralda, E., Paz-Ares, L., Otero, M.J., Nin, R. Mesia, Fernandez, A.M. Arance, Cervantes, A., Martin-Liberal, J., Gavilá-Gregori, J., Parraga, K. Amillano, Racca, F.E., Tabernero, J., and Prat, A.

Published
2023
Full Text
View/download PDF

28. 150P Validation of a genomic assay in early-stage HER2+ breast cancer (BC) treated with trastuzumab and pertuzumab (HP): A correlative analysis from PHERGain phase II trial

Author

Llombart Cussac, A., Pérez-García, J.M., Pare Brunet, L., Villacampa Javierre, G., Brasó-Maristany, F., Gion Cortes, M., Schmid, P., Colleoni, M.A., Ruiz Borrego, M., Galván, P., Parker, J., Perou, C.M., Villagrasa Gonzalez, P., Guerrero, J.A., Sampayo-Cordero, M., Mancino, M., Prat, A., and Cortés, J.

Published
2023
Full Text
View/download PDF

29. 149P Assessing the effect of single dose trastuzumab and pertuzumab (HP) on biological changes and pathological complete response (pCR) in ERBB2+ Breast Cancer: Results from the neoadjuvant BionHER study

Author

Gomez Serra, N., Brasó-Maristany, F., Fullana Grimalt, B., Ortega, R., Petit, A., Vicente, M., Falo, C., Stradella, A., Bañuls, M., Pare Brunet, L., Marín-Aguilera, M., Fernandez Ortega, A., Vethencourt, A., Cordero, D., Iserte, A., Galván, P., Perou, C.M., Villagrasa Gonzalez, P., Prat, A., and Pernas Simon, S.

Published
2023
Full Text
View/download PDF

35. 109P Subsequent therapies after progressing to CDK4/6 inhibition (CDK4/6i) in hormone receptor positive/HER2 negative (HR+/HER2-) advanced breast cancer (ABC)

Author

Laguna, J.C., Brasó-Maristany, F., Pascual, T., Rodriguez Hernandez, A., Chic, N., Schettini, F., Sanfeliu Torres, E., Gonzalez-Farre, B., Martínez, D., Galván, P., Díez-Guardia, V., Adamo, B., Vidal, M., Guillen Sacoto, M.C., Moreno, R., Prat, A., Muñoz, M., and Martínez-Sáez, O.

Published
2021
Full Text
View/download PDF

36. 23P CDK4/6 inhibition and endocrine therapy (ET) in the HER2-enriched subtype (HER2-E) in hormone receptor-positive/HER2-negative (HR+/HER2-) advanced breast cancer (ABC): A retrospective analysis of real-world data

Author

Martínez-Sáez, O., Tolosa, P., Sánchez De Torre, A., Pascual, T., Brasó-Maristany, F., Rodriguez Hernandez, A., Parrilla, L., Roncero, A.M., Ruano, Y., Chic, N., Schettini, F., Laguna, J.C., Sanfeliu Torres, E., Gonzalez-Farre, B., Vidal, M., Adamo, B., Guillen Sacoto, M.C., Muñoz, M., Prat, A., and Ciruelos, E.M.

Published
2021
Full Text
View/download PDF

38. 1481P Expression of ERBB2 and PD1 mRNA in advanced gastric cancer

Author

Pesántez, D., Brasó-Maristany, F., Esposito, F., Oberoi, H.K., Oliveres, H., Pascual, T., Cuatrecasas, M., Teixido Febrero, C., Sanfeliu, E., Laguna, J.C., Seguí, E., Pérez, A., Martínez, D., Guerrero, J., López, S., Fernández-Esparrach, G., Momblán, D., Fillat, C., Prat, A., and Sauri, T.

Published
2020
Full Text
View/download PDF

39. 168P Development of a combined clinical model to predict progression-free survival (PFS) in advanced breast cancer (ABC) treated with CDK4/6 inhibitors (CDK4/6i)

Author

Martínez-Sáez, O., Menichetti, A., Pare Brunet, L., Griguolo, G., Rodriguez Hernandez, A., Pascual, T., Dieci, M.V., Conte, P.F., Giorgi, C.A., Brasó-Maristany, F., Chic, N., Martínez, D., Rodríguez, A., Schettini, F., Conte, B., Vidal, M., Adamo, B., Muñoz, M., Prat, A., and Guarneri, V.

Published
2020
Full Text
View/download PDF

41. 12P Gene expression profiling in early breast cancer treated with neoadjuvant ribociclib plus letrozole (R+L) versus chemotherapy (CT): A correlative analysis of the SOLTI-1402/CORALLEEN phase II trial

Author

Chic, N., González-Farré, B., Paré, L., Pascual, T., Saura, C., Hernando Melia, C., Muñoz, M., Fernandez, P., Martínez, D., Sanfeliu, E., Brasó-Maristany, F., González-Farré, X., Oliveira, M., Gil-Gil, M., Celiz, P., Ciruelos, E.M., Villagrasa, P., Gavila Gregori, J., and Prat, A.

Published
2020
Full Text
View/download PDF

42. 5P Circulating tumour DNA (ctDNA) dynamics using a standardized multi-gene panel in advanced breast cancer patients (pts) treated with CDK4/6 inhibitors (CDK4/6i)

Author

Martínez-Sáez, O., Pascual, T., Brasó-Maristany, F., Chic, N., González-Farré, B., Sanfeliu, E., Rodríguez, A., Martínez, D., Galván, P., Rodriguez Hernandez, A., Schettini, F., Conte, B., Vidal, M.J., Adamo, B., Muñoz, M., Moreno, R., Ciruelos, E.M., Faull, I., Odegaard, J., and Prat, A.

Published
2020
Full Text
View/download PDF

44. 119P - ERBB2 mRNA as a predictor in HER2-positive (HER2+)/hormone receptor-positive (HR+) metastatic breast cancer (BC) treated with HER2 blockade in combination with endocrine therapy (ET): A retrospective analysis of the ALTERNATIVE and SOLTI-PAMELA trials

Author

Chic, N., Pascual, T., Brasó-Maristany, F., Villagrasa Gonzalez, P., Pare Brunet, L., Schettini, F., Conte, B., Adamo, B., Vidal, M., Muñoz, M., Martínez, O., Gonzalez-Farre, B., Cortés, J., Llombart-Cussac, A., Rodrik-Outmezguine, V., Izquierdo Delso, M.A., Schiff, R., Osborne, C.K., Rimawi, M., and Prat, A.

Published
2019
Full Text
View/download PDF

46. Clinical, pathological and PAM50 gene expression features of HER2-low breast cancer

Author

Miguel Martín, Laia Paré, Barbara Adamo, Roberta Fasani, Blanca Gonzalez-Farre, Benedetta Conte, Giovanna Sabarese, Carlos H. Barrios, Fara Brasó-Maristany, Esther Sanfeliu, Mariavittoria Locci, Giuseppe Perrone, Francesca Zalfa, Esther Barnadas, Olga Martínez-Sáez, Aranzazu Fernandez-Martinez, Ana Lluch, Maria Vidal, Joaquín Gavilá, Tomás Pascual, Aleix Prat, Francesco Schettini, Sabino De Placido, Patricia Villagrasa, Vicente Peg, Nuria Chic, Juan Miguel Cejalvo, Schettini, F., Chic, N., Braso-Maristany, F., Pare, L., Pascual, T., Conte, B., Martinez-Saez, O., Adamo, B., Vidal, M., Barnadas, E., Fernandez-Martinez, A., Gonzalez-Farre, B., Sanfeliu, E., Cejalvo, J. M., Perrone, G., Sabarese, G., Zalfa, F., Peg, V., Fasani, R., Villagrasa, P., Gavila, J., Barrios, C. H., Lluch, A., Martin, M., Locci, M., De Placido, S., Prat, A., Institut Català de la Salut, [Schettini F] Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy. Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain. SOLTI Breast Cancer Research Group, Barcelona, Spain. [Chic N] Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain. SOLTI Breast Cancer Research Group, Barcelona, Spain. Department of Medical Oncology, Hospital Clínic, Barcelona, Spain. [Brasó-Maristany F] Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain. Department of Medical Oncology, Hospital Clínic, Barcelona, Spain. [Paré L] SOLTI Breast Cancer Research Group, Barcelona, Spain. [Pascual T] Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain. SOLTI Breast Cancer Research Group, Barcelona, Spain. Department of Medical Oncology, Hospital Clínic, Barcelona, Spain. Department of Genetics, University of North Carolina, Chapel Hill, NC, USA. [Conte B] Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain. Department of Medical Oncology, Ospedale Policlinico San Martino, University of Genova, Genova, Italy. [Peg V] Vall d’Hebron Hospital Universitari, Barcelona, Spain. GEICAM, Grupo Español de Investigación en Cáncer de Mama, Madrid, Spain. [Fasani R] Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus

Subjects
0301 basic medicine, Oncology, medicine.medical_specialty, Neoplasms::Neoplasms by Site::Breast Neoplasms [DISEASES], Disease, Article, Càncer de mama, 03 medical and health sciences, 0302 clinical medicine, Breast cancer, Mama - Càncer, Internal medicine, Gene expression, Cancer genomics, Other subheadings::Other subheadings::/genetics [Other subheadings], Medicine, High activity, Pharmacology (medical), Radiology, Nuclear Medicine and imaging, skin and connective tissue diseases, Gene, Pathological, neoplasms, RC254-282, neoplasias::neoplasias por localización::neoplasias de la mama [ENFERMEDADES], Her2 expression, business.industry, Otros calificadores::Otros calificadores::/genética [Otros calificadores], Investigative Techniques::Genetic Techniques::Gene Expression Profiling [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Translational research, medicine.disease, Expressió gènica, 3. Good health, ERBB2 Amplification, técnicas de investigación::técnicas genéticas::perfiles de expresión génica [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], 030104 developmental biology, 030220 oncology & carcinogenesis, business
Abstract

Càncer de mama; Genòmica del càncer; Recerca translacional Cáncer de mama; Genómica del cáncer; Investigación traslacional Breast cancer; Cancer genomics; Translational research Novel antibody-drug conjugates against HER2 are showing high activity in HER2-negative breast cancer (BC) with low HER2 expression (i.e., 1+ or 2+ and lack of ERBB2 amplification). However, the clinical and molecular features of HER2-low BC are yet to be elucidated. Here, we collected retrospective clinicopathological and PAM50 data from 3,689 patients with HER2-negative disease and made the following observations. First, the proportion of HER2-low was higher in HR-positive disease (65.4%) than triple-negative BC (TNBC, 36.6%). Second, within HR-positive disease, ERBB2 and luminal-related genes were more expressed in HER2-low than HER2 0. In contrast, no gene was found differentially expressed in TNBC according to HER2 expression. Third, within HER2-low, ERBB2 levels were higher in HR-positive disease than TNBC. Fourth, HER2-low was not associated with overall survival in HR-positive disease and TNBC. Finally, the reproducibility of HER2-low among pathologists was suboptimal. This study emphasizes the large biological heterogeneity of HER2-low BC, and the need to implement reproducible and sensitive assays to measure low HER2 expression. This work was supported by the grants from the European Union’s Horizon 2020 Research and Innovation Programme under Grant agreement No. 847912 (to A.P.), the Instituto de Salud Carlos III-PI16/00904 (to A.P.), Pas a Pas (to A.P.), Save the Mama (to A.P.), Breast Cancer Now-2018NOVPCC1294 (to A.P.), Fundación Científica Asociación Española Contra el Cáncer-Ayuda Postdoctoral AECC 2017 (to F.B.-M.), Fundación SEOM, Becas FSEOM para Formación en Investigación en Centros de Referencia en el Extranjero 2018 (to T.P.) and PhD4MD - Departament de Salut expedient SLT008/18/00122 (to N.C.).

Published
2021

47. HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: a systematic review and meta-analysis

Author

Aranzazu Fernandez-Martinez, Barbara Adamo, Blanca Gonzalez-Farre, Lisa A. Carey, Francesco Schettini, Benedetta Conte, Charles M. Perou, Jamunarani Veeraraghavan, Jan C. Brase, Sabino De Placido, Tomás Pascual, Mariavittoria Locci, Pierfranco Conte, Patricia Villagrasa, Montserrat Muñoz, Sonia Pernas, Fara Brasó-Maristany, Olga Martínez, Patricia Galván, Maria Vidal, Mothaffar F. Rimawi, C. Kent Osborne, Carla Rognoni, Gaia Griguolo, Rachel Schiff, Nuria Chic, Valentina Guarneri, Aleix Prat, Schettini, F., Pascual, T., Conte, B., Chic, N., Braso-Maristany, F., Galvan, P., Martinez, O., Adamo, B., Vidal, M., Munoz, M., Fernandez-Martinez, A., Rognoni, C., Griguolo, G., Guarneri, V., Conte, P. F., Locci, M., Brase, J. C., Gonzalez-Farre, B., Villagrasa, P., De Placido, S., Schiff, R., Veeraraghavan, J., Rimawi, M. F., Osborne, C. K., Pernas, S., Perou, C. M., Carey, L. A., and Prat, A.

Subjects
0301 basic medicine, Oncology, medicine.medical_specialty, BIOMARKER, BREAST CANCER, HER2-ENRICHED, HER2-POSITIVE, PAM50, PATHOLOGIC COMPLETE RESPONSE, Receptor, ErbB-2, medicine.medical_treatment, Breast Neoplasms, Disease, Article, 03 medical and health sciences, 0302 clinical medicine, Breast cancer, ErbB-2, Internal medicine, Pathologic complete response, medicine, Biomarkers, Tumor, Humans, Radiology, Nuclear Medicine and imaging, PAM50, skin and connective tissue diseases, neoplasms, Neoadjuvant therapy, Neoplasm Staging, Chemotherapy, Tumor, business.industry, Remission Induction, Biomarker, HER2-Enriched, HER2-positive, Female, Neoadjuvant Therapy, General Medicine, Odds ratio, medicine.disease, Genomic Biomarker, 030104 developmental biology, 030220 oncology & carcinogenesis, Meta-analysis, Biomarker (medicine), business, Biomarkers, Receptor
Abstract

Background: HER2-positive (HER2+) breast cancer (BC) comprises all the four PAM50 molecular subtypes. Among these, the HER2-Enriched (HER2-E) appear to be associated with higher pathological complete response (pCR) rates following anti-HER2-based regimens. Here, we present a meta-analysis to validate the association of the HER2-E subtype with pCR following anti-HER2-based neoadjuvant treatments with or without chemotherapy (CT). Methods: A systematic literature search was performed in February 2019. The primary objective was to compare the association between HER2-E subtype (versus others) and pCR. Selected secondary objectives were to compare the association between 1) HER2-E subtype and pCR in CT-free studies, 2) HER2-E subtype within hormone receptor (HR)-negative and HR+ disease and 3) HR-negative disease (versus HR+) and pCR in all patients and within HER2-E subtype. A random-effect model was applied. The Higgins��� I2 was used to quantify heterogeneity. Results: Sixteen studies were included, 5 of which tested CT-free regimens. HER2-E subtype was significantly associated with pCR in all patients (odds ratio [OR] = 3.50, p < 0.001, I2 = 33%), in HR+ (OR = 3.61, p < 0.001, I2 = 1%) and HR-negative tumors (OR = 2.28, p = 0.01, I2 = 47%). In CT-free studies, HER2-E subtype was associated with pCR in all patients (OR = 5.52, p < 0.001, I2 = 0%) and in HR + disease (OR = 4.08, p = 0.001, I2 = 0%). HR-negative status was significantly associated with pCR compared to HR + status in all patients (OR = 2.41, p < 0.001, I2 = 30%) and within the HER2-E subtype (OR = 1.76, p < 0.001, I2 = 0%). Conclusions: The HER2-E biomarker identifies patients with a higher likelihood of achieving a pCR following neoadjuvant anti-HER2-based therapy beyond HR status and CT use. Future trial designs to escalate or de-escalate systemic therapy in HER2+ disease should consider this genomic biomarker.

Published
2020

48. Dual HER2 inhibition: mechanisms of synergy, patient selection, and resistance.

Author

Waks AG, Martínez-Sáez O, Tarantino P, Braso-Maristany F, Pascual T, Cortés J, Tolaney SM, and Prat A

Subjects
Humans, Female, Patient Selection, Drug Synergism, Molecular Targeted Therapy methods, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Biomarkers, Tumor genetics, Biomarkers, Tumor metabolism, Receptor, ErbB-2 antagonists & inhibitors, Receptor, ErbB-2 metabolism, Breast Neoplasms drug therapy, Breast Neoplasms genetics, Breast Neoplasms pathology, Drug Resistance, Neoplasm genetics, Protein Kinase Inhibitors therapeutic use
Abstract

HER2-targeted therapies for patients with HER2 + breast cancer are rapidly evolving, offering a range of more complex and personalized treatment options. Currently, an array of anti-HER2 monoclonal antibodies, tyrosine kinase inhibitors and antibody-drug conjugates are administered, sometimes alongside chemotherapy or endocrine therapy, both in curative and palliative contexts. However, the heterogeneous nature of HER2 + breast cancer demands a deeper understanding of disease biology and its role in responsiveness to novel HER2-targeted agents, as well as non-HER2-targeted therapies, in order to optimize patient outcomes. In this Review, we revisit the mechanisms of action of HER2-targeted agents, examine the evidence supporting the use of dual HER2 blockade in patients with HER2-amplified tumours, and explore the role of biomarkers in guiding future treatment strategies. We also discuss potential implications for the future treatment of patients with HER2 + breast cancer., (© 2024. Springer Nature Limited.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results